ATAC - Arimidex, Tamoxifen Alone or in Combination
Study identifier:1033IL/0029
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Double Blind Trial Comparing Arimidex Alone with Nolvadex Alone with Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women with Breast Cancer
Medical condition
Breast Cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Anastozole (Arimidex), Tamoxifen (Nolvadex), Anastozole (Arimidex) placebo, Tamoxifen (Nolvadex) placebo
Sex
Female
Actual Enrollment
9358
Study type
Interventional
Age
45 Years +
Date
Study Start Date: 01 Jul 1996
Primary Completion Date: 01 Jun 2001
Study Completion Date: 01 Apr 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jun 2012 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 Arimidex 1mg + Nolvadex placebo | Drug: Anastozole (Arimidex) 1mg, orally, once daily Other Name: Arimidex Drug: Tamoxifen (Nolvadex) placebo 20mg, orally, once daily |
| Active Comparator: 2 Arimidex placebo + Nolvadex 20mg | Drug: Tamoxifen (Nolvadex) 20mg, orally, once daily Other Name: Nolvadex Drug: Anastozole (Arimidex) placebo 1mg, orally, once daily |
| Active Comparator: 3 Arimidex 1mg + Nolvadex 20mg | Drug: Anastozole (Arimidex) 1mg, orally, once daily Other Name: Arimidex Drug: Tamoxifen (Nolvadex) 20mg, orally, once daily Other Name: Nolvadex |
